On the 27^th November 2025, Anthi Chalou presented her progress in her PhD studies in Malmö, Sweden.

This review marks the half-way point of completing her PhD studies, wherein she is exploring the mechanisms and cellular targets of immune checkpoint inhibition-elicited cardiovascular inflammation. By better understanding these mechanisms, new clinical strategies preserving the potent anti-tumor effects of immune checkpoint inhibition treatment while also mitigating negative cardiovascular effects may be developed.